1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 62/085,722, filed Dec 1, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,616,063 | 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE In force · High confidence | AstraZeneca AB | In force | High confidence | ||
| US 10,016,430 | 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | ||
| US 11,000,525 | 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE In force · Low confidence | AstraZeneca AB | In force | Low confidence | ||
| US 12,569,489 | 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE In force · Low confidence | AstraZeneca AB | In force | Low confidence | ||
| US 11,975,004 | 1-[2-(AMINOMETHYL)BENZYL]-2-Thioxo-1,2,3,5-Tetrahydro-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE In force · Low confidence | AstraZeneca AB | In force | Low confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.